Titre:
  • Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Auteur:Dowsett, Mitch; Allred, Craig; Knox, Jill; Quinn, Emma; Salter, Janine; Wale, Chris; Houghton, Joan; Houghton, Joan; Williams, Norman; Mallon, Elizabeth; Bishop, Hugh; Ellis, Ian; Larsimont, Denis; Sasano, Hironobu; Carder, Pauline; Cussac, Antonio Llombart; Knox, Fiona; Speirs, Valerie; Forbes, John F; Buzdar, Aman
Informations sur la publication:Journal of clinical oncology, 26, 7, page (1059-1065)
Statut de publication:Publié, 2008-03
Sujet CREF:Cancérologie
MeSH keywords:Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism
Chemotherapy, Adjuvant
Double-Blind Method
Female
Humans
Middle Aged
Neoplasm Recurrence, Local -- etiology -- pathology
Nitriles -- administration & dosage
Postmenopause
Prognosis
Receptor, erbB-2 -- metabolism
Receptors, Estrogen -- metabolism
Receptors, Progesterone -- metabolism
Retrospective Studies
Survival Rate
Tamoxifen -- administration & dosage
Time Factors
Tissue Array Analysis
Treatment Outcome
Triazoles -- administration & dosage
Note générale:Journal Article
Randomized Controlled Trial
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2007.12.9437
info:pii/JCO.2007.12.9437
info:scp/41949104971
info:pmid/18227529